A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
← catalyst calendarSponsored by Transgene (industry) · TNG.PA — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
22actual
Sites
5
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision not related to safety
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-05 | actual | When the study began enrolling |
| Primary completion | 2025-06-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-23 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Intervention
- Drug: TG6050
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
measured Up to 5 years
Publications
- PMID 39060022 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TNG.PA's whole pipeline · Catalyst calendar · Every registered study · What changed